Zeta Health Solutions’ Post

🚀 Diving into the Eurasian pharmaceutical market trends: an Interview with Anastasia Kruglova As we gear up for the 5th Eurasian Pharmaceutical Summit, the Global Pharmaceutical Leaders’ Club presents an exclusive interview with Anastasia Kruglova, General Director of IQVIA in Russia and Eurasia. In conversation with Natalia Baeva, Director of GPLC, they discuss the key trends and challenges in the Eurasian pharmaceutical markets, the region's potential, and the impact of global trends on local realities. Key highlights of the interview: 🔹 Major barriers: Why does the absence or minimal level of reimbursement remain a key obstacle for the development of Eurasian markets? 🔹 Global trends: Which global trends in pharma and R&D are actively influencing the growth of regional markets? 🔹 Data transparency: How does the lack of accurate data hinder development, and what is needed to improve data quality? 🔹 Promising markets: Which countries in the region are in the spotlight for analysts and pharmaceutical companies? 🔹 Challenges for pharma companies: How are pharmaceutical companies adapting to new conditions, and how do IQVIA's solutions support them on this path? IQVIA as a leading global provider of advanced analytics and technology solutions in healthcare actively supports the Eurasian Pharmaceutical Summit by offering innovative approaches and deep expertise for analyzing all segments of the pharmaceutical market. 📌 Read the full interview with Anastasia Kruglova on our website to learn more about analytical trends, barriers, and opportunities that await pharmaceutical companies in Eurasia! 🔗 Read the full interview on our website >>>https://lnkd.in/dyvzVisj #EurasianPharmaceuticalSummit #EPS2024 #IQVIA #pharma #GlobalPharmaLeadersClub #trends #reimbursement #marketanalysis

🚀 Diving into the Eurasian pharmaceutical market trends: an Interview with Anastasia Kruglova As we gear up for the 5th Eurasian Pharmaceutical Summit, the Global Pharmaceutical Leaders’ Club presents an exclusive interview with Anastasia Kruglova, General Director of IQVIA in Russia and Eurasia. In conversation with Natalia Baeva, Director of GPLC, they discuss the key trends and challenges in the Eurasian pharmaceutical markets, the region's potential, and the impact of global trends on local realities. Key highlights of the interview: 🔹 Major barriers: Why does the absence or minimal level of reimbursement remain a key obstacle for the development of Eurasian markets? 🔹 Global trends: Which global trends in pharma and R&D are actively influencing the growth of regional markets? 🔹 Data transparency: How does the lack of accurate data hinder development, and what is needed to improve data quality? 🔹 Promising markets: Which countries in the region are in the spotlight for analysts and pharmaceutical companies? 🔹 Challenges for pharma companies: How are pharmaceutical companies adapting to new conditions, and how do IQVIA's solutions support them on this path? IQVIA as a leading global provider of advanced analytics and technology solutions in healthcare actively supports the Eurasian Pharmaceutical Summit by offering innovative approaches and deep expertise for analyzing all segments of the pharmaceutical market. 📌 Read the full interview with Anastasia Kruglova on our website to learn more about analytical trends, barriers, and opportunities that await pharmaceutical companies in Eurasia! 🔗 Read the full interview on our website >>>https://lnkd.in/deQtbKqe #EurasianPharmaceuticalSummit #EPS2024 #IQVIA #pharma #GlobalPharmaLeadersClub #trends #reimbursement #marketanalysis

All I see in all your post is an attempt to make the case that Africa is not good for investment in pharma production If that seems the case, I apologize. But let me be clear: there is room for investment in the development of pharmaceuticals in Africa. Increasing healthcare demands, a growing middle class, a growing population, and improved infrastructure in some areas are some of the elements that can draw pharmaceutical companies to Africa. #investinAfrica medicines for Africa (mfa)

🚀 China's Biotech Boom: A Global Innovation Hub 🌍 China's biotechnology sector is gaining global momentum, now contributing 23% of drug candidates in development—second only to the U.S. Thanks to regulatory reforms starting in 2015, China’s focus has shifted from generics to cutting-edge drug development. The National Medical Products Administration (NMPA) has streamlined approval processes, slashing review times for new drug applications from nearly 2 years to just 3 months. ⏱️ This shift has attracted major investments and positioned China as a hub for pharmaceutical innovation. With R&D spending now surpassing the EU and approaching U.S. levels, China is fast becoming a key player in the global biotech landscape. 🌐🔬 China’s biotech industry is poised for continued growth and global impact 💡 "When I’m talking to pharmaceutical executives, when they talk about China and Chinese research, they are overwhelmed by the speed and the energy", Michael Ward, global head of life sciences and healthcare thought leadership, Clarivate. Good report from Clarivate as well ! #Biotech #Innovation #geopolitics

SFBN Feed: MarketingRx roundup: Study finds generic drugs gain ground, but docs still prefer brands; Pfizer lauded at AACR https://lnkd.in/gxk2zKDn Generic drugs still passed over for brands, study finds: While more doctors are prescribing generic drugs, the majority of doctors still prefer brand name drugs, according to a new GlobalData survey. Almost 40% of physicians [...] #BayArea #SanFrancisco #Biotech #Lifescience #News

Global Pharma’s Strategic Expansion into China’s Booming Biotech Sector China's biotech industry is thriving, drawing significant investment from global pharmaceutical companies. Driven by a robust national sector, international players are increasingly collaborating with local biotech firms to capitalize on innovation and expand their reach in the growing Chinese market. This surge reflects China’s strategic position as a key player in the future of global healthcare. #PharmaInChina #BiotechGrowth #HealthcareInnovation #GlobalExpansion #ChinaBiotech #PharmaceuticalInvestments #BiotechCollaboration #EmergingMarkets #PharmaTrends

💹 Investments by foreign companies in the #BioRegion between 2019 and 2023 experienced an exceptional growth: 💸 €1,684 million in direct investment 👩🔬 More than 4,600 jobs created In just the 1st half of 2023, #investment was up 110% on the previous year, and #employment by 366%. 👉 This boost is mainly the result of the announcement by the #pharma multinational AstraZeneca and its division focused on rare  diseases, Alexion Pharmaceuticals, Inc., regarding the establishment of its R&D hub in #Barcelona. ➕ More data in the #BioRegionReport 2023:  https://report.biocat.cat/ Promoted by: Biocat, BioRegion of Catalonia With the support of: Amgen, Almirall, AstraZeneca, Cuatrecasas, ESTEVE, and Sanofi. In collaboration with: CataloniaBio & HealthTech, ACCIÓ, Farmaindustria, and Fenin, Federación Española de Empresas de Tecnología Sanitaria.

🚀 Microcarriers Market Outlook: A Global Perspective 🚀 Download Free Sample Report@https://lnkd.in/dAU-cYRh 🌍 North America: ◼ US: Regulatory approvals for cell & therapy products are on the rise, fueling market growth. ◼ Canada: Demand for biologics is surging, driving market expansion. 🌍 Europe: ◼ Germany: Increased R&D investments in life sciences are propelling the market forward. ◼ UK: A growing focus on oncology therapeutics is boosting demand. ◼ France: Biotech clusters are gaining attention, driving market growth. ◼ Italy: Rising demand for therapeutics is supporting market expansion. ◼ Spain: Growing interest in biopharmaceuticals is bolstering the market. 🌍 Asia Pacific: ◼ China: The bioprocessing industry is experiencing significant growth, driving market dynamics. ◼ Japan: Favorable regulatory support for drug discovery & development is enhancing market potential. ◼ India: Rising pharmaceutical R&D spending is propelling market growth. ◼ South Korea: Demand for biosimilars is contributing to market expansion. 🌍 Latin America: ◼ Brazil: Focus on vaccine development is supporting market growth. ◼ Mexico: Expansion of pharma & biopharma companies is boosting demand. 🌍 Middle East & Africa: ◼ Middle East: Favorable government investments in biotech research are driving demand. ◼ Africa: Increased government focus on clinical trial approvals is supporting market growth. #Microcarriers #Biotech #LifeSciences #MarketGrowth #RecessionImpact #GlobalMarkets #Innovation #Healthcare #Pharmaceuticals #R&D #Bioprocessing #Oncology #Vaccines #Biosimilars

Driving Factors for Growth in #Biosimilar Testing and Development Services Market The surge in demand for biosimilars as a cost-effective alternative to biological drugs, coupled with the rising prevalence of chronic diseases globally, is propelling the growth of the biosimilar testing and development services market.The biosimilar testing market size is expected to grow significantly, owing to a surge in the need for #biosimilartesting facilities to meet the growing demand for biosimilar medicines and the rise in outsourcing of preclinical, clinical, and laboratory testing services by pharma and biotech companies. Key Market Players: BioPharmaSpec, Profacgen , Element Materials Technology, Veeda Clinical Research Limited , SGS, INTERTEK GROUP PLC, Eurofins Scientific Finland Oy, Pacific BioLabs, Inc., Sartorius Want To Know More:https://lnkd.in/dH8ZWKK2 #BiosimilarMarket #BiologicalDrugs #ChronicDiseases #Healthcare #BiosimilarTesting #MedicalResearch #CancerStatistics #DrugDevelopment #HealthcareTrends #CostEffectiveMedicine